Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
The current Neurocrine(NBIX) stock price is $151.96, with a market capitalization of 15.14B. The stock trades at a price-to-earnings (P/E) ratio of 36.41.
On 2025-12-04, Neurocrine(NBIX) stock traded between a low of $149.44 and a high of $154.35. Shares are currently priced at $151.96, which is +1.7% above the low and -1.5% below the high.
The Neurocrine(NBIX)'s current trading volume is 791.17K, compared to an average daily volume of 930.88K.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $157.67 at its peak.
During the past year, Neurocrine(NBIX) stock moved between $84.23 at its lowest and $157.67 at its peak.
NBIX News
On November 20, 2025, Neurocrine Biosciences announced the publication of a comprehensive peer-reviewed narrative review consolidating over a decade of clinical...
Neurocrine Biosciences (NBIX) has drawn fresh attention following the release of a detailed peer-reviewed narrative review on its FDA-approved VMAT2 inhibitors,...
Image source: The Motley Fool. Tuesday, Oct. 28, 2025 at 9:31 p.m. ET Call participants Chief Executive Officer — Kyle Gano Chief Financial Officer — Matthew A...
Analyst ratings
90%
of 30 ratingsMore NBIX News
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and delive...
If you have ever wondered whether Neurocrine Biosciences deserves a spot in your portfolio, you are not alone. Figuring out its fair value is where smart invest...